Vaccine review: "Staphyloccocus aureus vaccines: problems and prospects". (Q38102491)

28 August 2017

Vaccine review: "Staphyloccocus aureus vaccines: problems and prospects". (English)

1 reference

28 August 2017

1 reference

1

Kathrin U Jansen

1 reference

28 August 2017

Douglas Q Girgenti

2

1 reference

28 August 2017

Ingrid L Scully

series ordinal

3

1 reference

28 August 2017

Annaliesa S Anderson

series ordinal

4

1 reference

28 August 2017

language of work or name

English

0 references

publication date

23 April 2013

1 reference

28 August 2017

1 reference

28 August 2017

31

1 reference

28 August 2017

25

1 reference

28 August 2017

2723-2730

1 reference

How Staphylococcus aureus adapts to its host

28 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

The role of nasal carriage in Staphylococcus aureus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Poor functional status as a risk factor for surgical site infection due to methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Surgical-site infection rates and risk factor analysis in coronary artery bypass graft surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

The effect of increasing age on the risk of surgical site infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Prevalence and risk factor analysis for methicillin-resistant Staphylococcus aureus nasal colonization in children attending child care centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Severe neutropenia at time of port insertion is not a risk factor for catheter-associated infections in children with acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Hospitalization earlier than 1 year prior to admission as an additional risk factor for methicillin-resistant Staphylococcus aureus colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Specificity for human hemoglobin enhances Staphylococcus aureus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Use of a human-like low-grade bacteremia model of experimental endocarditis to study the role of Staphylococcus aureus adhesins and platelet aggregation in early endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Community-associated methicillin-resistant Staphylococcus aureus prevalence: how common is it? A methodological comparison of prevalence ascertainment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Treatment and recurrence management of staphylococcal infections: community-acquired MRSA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Staphylococcus aureus: a community pathogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Update on the prevention and control of community-acquired meticillin-resistant Staphylococcus aureus (CA-MRSA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Molecular mechanisms of Staphylococcus aureus nasopharyngeal colonization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

What determines nasal carriage of Staphylococcus aureus?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Host defense and pathogenesis in Staphylococcus aureus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Is Staphylococcus aureus an intracellular pathogen?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Metal ion acquisition in Staphylococcus aureus: overcoming nutritional immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Emerging themes in manganese transport, biochemistry and pathogenesis in bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

The battle for iron between bacterial pathogens and their vertebrate hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Mn2+ and bacterial pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

A play in four acts: Staphylococcus aureus abscess formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Bacterial adhesion to animal tissues: protein determinants for recognition of extracellular matrix components.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Adhesion mechanisms of staphylococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Review article: The role of CD4(+) T cells in ANCA-associated systemic vasculitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Recognition of Staphylococcus aureus by the innate immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Return of the Trojan horse: intracellular phenotype switching and immune evasion by Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Recurrent infections and immune evasion strategies of Staphylococcus aureus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Innate and adaptive immune responses against Staphylococcus aureus skin infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Immunopathogenesis of Staphylococcus aureus pulmonary infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Challenges for a universal Staphylococcus aureus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Progress toward a Staphylococcus aureus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

IL-6 induced by Staphylococcus aureus infection prevents the induction of skin allograft acceptance in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

IgG opsonization of bacteria promotes Th17 responses via synergy between TLRs and FcγRIIa in human dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Host response signature to Staphylococcus aureus alpha-hemolysin implicates pulmonary Th17 response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Divergent roles of Toll-like receptor 2 in response to lipoteichoic acid and Staphylococcus aureus in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Superantigenic Staphylococcus aureus stimulates production of interleukin-17 from memory but not naive T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Staphylococcus aureus-derived extracellular vesicles induce neutrophilic pulmonary inflammation via both Th1 and Th17 cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Staphylococcal alpha-toxin is a strong inducer of interleukin-17 in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Characterization of the mechanism of protection mediated by CS-D7, a monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Murine immune response to a chronic Staphylococcus aureus biofilm infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Selective immunodeficiency affecting staphylococcal response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

How do neutrophils and pathogens interact?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

The signaling mechanisms underlying cell polarity and chemotaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

The role of superoxide anion generation in phagocytic bactericidal activity. Studies with normal and chronic granulomatous disease leukocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Pyogenic bacterial infections in humans with IRAK-4 deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Is there a future for a Staphylococcus aureus vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Perioperative management of neurosurgical patients with methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Osteomyelitis: clinical update for practical guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

The antibiotic challenge: changing clinical management of infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Vancomycin resistance in staphylococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Effectiveness of barrier precautions and surveillance cultures to control transmission of multidrug-resistant organisms: a systematic review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Staphylococcus aureus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Current status of group A streptococcal vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Antibody to Capsular Polysaccharides of Streptococcus pneumoniae: Prevalence, Persistence, and Response to Revaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Staphylococcus aureus FhuD2 is involved in the early phase of staphylococcal dissemination and generates protective immunity in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Selection and characterization of murine monoclonal antibodies to Staphylococcus aureus iron-regulated surface determinant B with functional activity in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

The rise and rise of Staphylococcus aureus: laughing in the face of granulocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Surface adhesins of Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Vaccine assembly from surface proteins of Staphylococcus aureus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Passive immunization as prophylaxis: when and where will this work?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Staphylococcal vaccines and immunotherapy: to dream the impossible dream?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Vaccine protection against Staphylococcus aureus pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Innate immune dysfunctions in aged mice facilitate the systemic dissemination of methicillin-resistant S. aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Risk factors for neurosurgical site infections after craniotomy: a critical reappraisal of antibiotic prophylaxis on 4,578 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Infection of the surgical site after arthroplasty of the hip.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Risk factors for surgical site infections following spinal fusion procedures: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Surgical site infections occurring after hospital discharge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Risk factors for surgical site infection following caesarean section in England: results from a multicentre cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Increase in the rate of sternal surgical site infection after coronary artery bypass graft: a marker of higher severity of illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Wound infections after hysterectomy: opportunities for practice improvement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Breast augmentation, antibiotic prophylaxis, and infection: comparative analysis of 1,628 primary augmentation mammoplasties assessing the role and efficacy of antibiotics prophylaxis duration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Exposure to hospital roommates as a risk factor for health care-associated infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Infected aortic aneurysms: clinical outcome and risk factor analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Risk factors for hospital-acquired Staphylococcus aureus bacteremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Prospective nationwide surveillance of surgical site infections after gastric surgery and risk factor analysis in the Korean Nosocomial Infections Surveillance System (KONIS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Risk factors for surgical wound infection and bacteraemia following coronary artery bypass surgery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Risk factors for postoperative mediastinitis due to methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

A 12-year review of Staphylococcus aureus bloodstream infections in haemodialysis patients: more work to be done

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Immune abnormalities in renal failure and hemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Imbalanced cytokine secretion in newborns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Defective macrophage function in neonates and its impact on unresponsiveness of neonates to polysaccharide antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Innate cellular immune responses in newborns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.002

10.1016/J.VACCINE.2013.04.002

7 January 2021

Identifiers

DOI

1 reference

28 August 2017

1 reference